Top 50 Medical Startup Investors in Sweden

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

We co-found companies, dedicating our in-house team of designers, developers, and marketers to bring ideas to life. With every venture we co-found, our mission is to advance the consumer experience across industries with world-class technology, data-informed design, and lots of heart. Are you an entrepreneur who shares our mission?

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Sophia Bendz - Partner @ Cherry Ventures

We support early-stage founders in building global, category-defining companies. From Seed to IPO and beyond.

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Bonit Capital is a Swedish family-owned investment company. We invest across sectors and asset classes, including social investments and outcome models.Venture Capital - We invest in ambitious founders within the life science sector. We take an active ownership approach by providing capital, industry expertise and access to an internationalnetwork. Our focus areas are digital health, medical technology and diagnostics.Private Equity - We invest in entrepreneurial teams with deep sector expertise and unique market access, primarily in the lower to mid-market buyout segment, with the aim to produce superior returns and meaningful portfolio diversification.Listed Equity - Our strategy is to obtain a broad market exposure through mainly external mandates, and to seek superior returns in individual shares primarily in life science. Among Bonit's main holdings are the world-leading medtech company Elekta AB, founded by Laurent Leksell.Leksell Social Ventures - LSV is the first impact investor in Sweden with a focus on outcome models and direct investments in the areas of mental health, education and social integration. Striving for systemic change, LSV contributes to social innovation and societal development by giving social entrepreneurs and social ideas the necessary prerequisites to develop and progress – through financing, idea development and networking with private, public and nonprofit actors.

Tim Jackson is the Founder, CEO, General Partner & Partner of Walking Ventures & he attended University of Oxford in in 1983.

Per Båtelson

Fåhraeus Startup and Growth is a venture capital fund that invests early in life science and tech companies.

Equity investment company doing Series A to late growth, private and public. Agile and long-term with no fixed holding period.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

Project A is an early-stage venture capital firm, combining financial and operational support for technology companies. In addition to $600 M in assets under management, Project A provides its portfolio companies with a wide range of operational support services. This includes more than 100 experts from key areas such as software engineering,business intelligence, marketing, and recruiting. The portfolio includes companies such as Trade Republic, sennder, KRY, Catawiki, WorldRemit, Spryker, and Voi.

Sting – Stockholm Innovation & Growth enables talented people to turn their ideas into sustainable businesses. The support they offer includes qualified coaching in business development, a business angel network, a venture capital fund, a recruitment service, and an international network of investors, business contacts and experts. Itcontribute to the success of Sweden’s future technology companies by helping them to grow and compete internationally.

Heartcore Capital invests in companies re-enchanting the world through technology.

Josefin Landgård is the Founder and CEO of Mantle. Previously she served as the Co-Founder and COO at KRY back in March 2014 to September 2018.

3T Invest started an interesting and fulfilling journey back in 2009. From the beginning they focused on the establishment of sustainable Venture Capital, supporting innovation and entrepreneurship. they are always committed to backing outstanding entrepreneurs with the necessary resources.

Born 1954. Degree from the Stockholm School of Economics and Master of Business Administration from Anderson School of Management, UCLA, USA.Board Member: AB Volvo, Stockholm School of Economics, and Handelshögskoleföreningen at Stockholm School of Economics.Principal work experience and other information: Vice President of the Royal SwedishAcademy of Engineering Sciences since 2014. President and CEO of AB Industrivärden 2001-2015. CFO and Executive Vice President of Skanska AB 1997–2001. Director Capital Markets Nordbanken 1996–1997. CFO and Executive Vice President of Securum AB 1992–1996. President of OM International AB 1987–1992. Previous positions within STC Scandinavian Trading Co AB and AB Wilhelm Becker. Board member in Telefonaktiebolaget LM Ericsson 2006-2013. Honorary Doctorate of Economics at Stockholm School of Economics.

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

We boldly invest in and support promising startups and potential innovations that explore new uses for sustainably-grown Nordic wood.

We are a team of entrepreneurs and investment professionals, building digital platforms to empower Brazilians. Since 2016, we have partnered with leading Swedish technology companies to build, invest and support successful companies in Brazil.

Zentynel Frontier is a investment firm.

Lars Lidgren is the Founder at Bonesupport.

Laurent Leksell

Flerie is an active long-term life science investor, focusing on biotech and pharmaceutical investments globally.

20 North Street is the name HDR Partners uses when adding investors and industrial experience to small growth companies.

KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.

Simon Fredriksson is the Co-Founder and CEO of Pixelgen Technologies. He attended Stanford University School of Medicine in 2003.

Jovitech Invest help entrepreneur-led companies to grow profitably through active, long-term ownership

Ferd er et familieeid investeringsselskap som er eid av femte og sjette generasjon Andresen.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

Investing in the crazy before it becomes normal

Kelly Gale

Jonas Fagerström

Jesper Broström

Premium domains add authority to your site. Transparent pricing. 1 year WHOIS privacy included. 30-day money back guarantee.

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

DHS Ventures, Stockholm School of Economics alumni angel investing network that invests early on into inovative companies.

John Bloom John C. Bloom holds a B.S. degree in biology from the University of Pittsburgh and doctorates in veterinary medicine and experimental hematology from the University of Pennsylvania. He completed his postdoctoral training at the Jefferson Medical College in hematology/oncology and served on the Faculty of the University off Pennsylvania School of Veterinary Medicine as Chief, Clinical Laboratory Medicine, before joining Smith Kline & French Laboratories as Associate Director of Pathology. Dr. Bloom has been active in the fields of toxicology, clinical risk assessment and translational biomarker research within the pharmaceutical industry, FDA and Institute of Medicine and has authored several manuscripts, chapters, reviews and texts on these topics. He served as Head, Clinical Pathology, in the Toxicology Division of Lilly Research Laboratories, where he subsequently moved to the Medical Division to establish the departments of Experimental Medicine and Clinical Diagnostic Services, which were responsible for translational biomarker research; and laboratory, ECG, imaging and specimen banking support for global clinical development, respectively. Upon his retirement from Lilly in 2009 he established Bloom Consulting Services, LLC, which he serves as President, and was appointed Consultant, Office of the Center Director, FDA. Dr. Bloom holds adjunct academic appointments at the University of Pennsylvania and Purdue University.